Jianting Long
Impact in
- Otorhinolaryngology top 2%
- Head and Neck Cancer Studies
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
-
- MicroRNA in disease regulation 6
- Cancer-related molecular mechanisms research 3
-
- Hepatocellular Carcinoma Treatment and Prognosis 6
- Co-authors
- Qiangsheng Dai (10 shared papers)Heping Li (8 shared papers)Baoxian Liu (9 shared papers)Fang Shi (4 shared papers)Chunlin Jiang (6 shared papers)Ruifang Zeng (4 shared papers)Ming Kuang (6 shared papers)Xiao-yan Xie (7 shared papers)
- Journals
- Tumor Biology (4 papers)BMC Cancer (4 papers)Scientific Reports (3 papers)OncoTargets and Therapy (3 papers)Journal of Experimental & Clinical Cancer Research (2 papers)
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Jianting Long
56 papers receiving 1.7k citations
Jianting Long's Hit Papers
Peers
Comparison fields: 5 of 105
- Otorhinolaryngology 195
- Cancer Research 438
- Oncology 369
- Hepatology 88
- Molecular Biology 743
Countries citing papers authored by Jianting Long
This map shows the geographic impact of Jianting Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianting Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianting Long more than expected).
Fields of papers citing papers by Jianting Long
This network shows the impact of papers produced by Jianting Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianting Long. The network helps show where Jianting Long may publish in the future.
Co-authors
The 25 scholars most cited alongside Jianting Long, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2021 | 330 |
| 2 | 2022 | 160 | |
| 3 | 2014 | 114 | |
| 4 | 2013 | 85 | |
| 5 | 2010 | 77 | |
| 6 | 2017 | 72 | |
| 7 | 2014 | 63 | |
| 8 | 2015 | 56 | |
| 9 | 2015 | 51 | |
| 10 | 2019 | 49 | |
| 11 | 2017 | 48 | |
| 12 | 2015 | 46 | |
| 13 | 2019 | 38 | |
| 14 | 2023 | 37 | |
| 15 | 2018 | 34 | |
| 16 | 2013 | 29 | |
| 17 | 2016 | 27 | |
| 18 | 2013 | 24 | |
| 19 | 2020 | 23 | |
| 20 | 2019 | 23 |
About Jianting Long
Jianting Long is a scholar working on Cancer Research, Hepatology, Molecular Biology, Oncology and Hematology, having authored 60 papers that have together received 1.7k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), MicroRNA in disease regulation (6 papers), RNA modifications and cancer (5 papers), Circular RNAs in diseases (4 papers), RNA Interference and Gene Delivery (3 papers), Cancer-related molecular mechanisms research (3 papers), Immunotherapy and Immune Responses (3 papers) and Leaf Properties and Growth Measurement (2 papers). The work is most often cited by research in Otorhinolaryngology (195 citations), Cancer Research (438 citations), Oncology (369 citations), Hepatology (88 citations) and Molecular Biology (743 citations). Jianting Long has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Qiangsheng Dai, Heping Li, Baoxian Liu, Fang Shi, Chunlin Jiang, Ruifang Zeng, Ming Kuang, Xiao-yan Xie, Shi Fang and Meihua Qu. Their work appears in journals such as Tumor Biology, BMC Cancer, Scientific Reports, OncoTargets and Therapy and Journal of Experimental & Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.